Does omalizumab increase the risk of malignancy? A retrospective case-control study in a single tertiary hospital
Asia Pac Allergy
.
2024 Mar;14(1):42-43.
doi: 10.5415/apallergy.0000000000000137.
Epub 2024 Mar 5.
Authors
Hyun Jee Kim
1
2
,
Suh Young Lee
3
,
Sang-Heon Cho
3
4
,
Hye-Ryun Kang
1
3
4
Affiliations
1
Drug Safety Center, Seoul National University Hospital, Seoul, Korea.
2
Department of Pharmacy, Seoul National University Hospital, Seoul, Korea.
3
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
4
Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul, Korea.
PMID:
38482458
PMCID:
PMC10932485
DOI:
10.5415/apallergy.0000000000000137
No abstract available